Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Yonglin Pu

TitleProfessor
InstitutionUniversity of Chicago
DepartmentRadiology-Nuclear Medicine
AddressChicago IL 60637
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    I am a board certified nuclear radiologist by the American Board of Nuclear Medicine, American Board of Radiology and American Board of Nuclear Cardiology. I am a reviewer of 16 international journals including Journal of Nuclear Medicine; European Journal of Nuclear Medicine and Molecular Imaging; Proceedings of the National Academy of Sciences (PNAS); International Journal of Computer Assisted Radiology and Surgery; PLOS ONE; Academic Radiology; Cancer Control Journal: Journal of the Moffitt Cancer Center; Medical Physics; International Journal of Radiation Oncology, Biology, Physics; Theranostics and Lung Cancer Management published by Future Medicine. I am an editorial board member of Chinese Journal of Cancer Research. I am also a reviewer of the Self-Assessment Module (SAM) for the American Board of Radiology.

    My research experience includes metabolic tumor imaging and quantification from FDG PET/CT imaging, and the impact of metabolic tumor burden on the long-term outcomes of patients with non-small cell lung cancer (NSCLC). I was the contact co-PI of an NIH (NCI) funded R21 project for developing the new PET volumetric prognostic (PVP) staging for NSCLC. My research experience also includes brain functional imaging and brain MRS as well as computer-aided diagnosis in PET/CT and bone scintigraphy.

    I have authored and co-authored more than 60 original peer-reviewed scientific research papers, six peer-reviewed proceeding papers, two non-peer-reviewed letters to editors and five non-peer-reviewed review papers in the field of medicine. I am the senior corresponding author of the article [Eur J Nucl Med Mol Imaging, 2012; 39(1): 27-38. https://www.ncbi.nlm.nih.gov/pubmed/21946983] that won the Springer Award in 2016 for the Most Cited Paper of the Eur J Nucl Med Mol Imaging (https://link.springer.com/article/10.1007/s00259-016-3538-7).


    Collapse Biography 
    Collapse education and training
    Beijing Medical University, BeijingMD Equivalent 08/1984Medicine
    Beijing Medical University, BeijingPHD08/1989Radiology
    Weil Medical College of Cornell University, New YorkResidency06/2004Radiology
    Mallinckrodt Institute of Radiology at Washington University, St. Louis, MOResidency06/2003Nuclear Medicine
    Collapse awards and honors
    2016Most cited paper in European Journal of Nuclear Medicine and Molecular Imaging, European Association of Nuclear Medicine and Springer
    2016Certifier for Highly Cited Research , Academic Radiology
    2014 - 2018Grant reward (R21): Developing a PET Volumetric Staging System for NSCLC, The National Cancer Institute of the National Institutes of Health
    2006Marc Tetalman Award for Outstanding Teaching, Department of Radiology of the university of Chicago
    2003Roentgen Resident/Fellow Research Award , Radiological Society of North America Research & Education Foundation

    Collapse Research 
    Collapse research activities and funding
    5R21CA181885     (Yonglin Pu and Yulei Jiang,)Sep 22, 2014 - Feb 28, 2018
    NCI/NIH
    Developing a PET Volumetric Staging System for NSCLC: a Complement to TNM Staging.
    Role Description: Current treatment of the most common form of lung cancer depends on whether the cancer is confined within one lung or has spread to near-by lymph nodes or even distant organs, but does not take into account the size and metabolic activity of the cancer either in its original site or in lymph nodes or other organs. PET/CT scans provide tumor metabolic volume information, which we will use to develop a new staging method for doctors to use in determining more appropriate treatment for lung cancer. Our new staging method with tumor metabolic volume information can potentially lead to better cancer-treatment outcomes, thereby benefiting many patients who suffer from this most common form of cancer in the world.
    Role: Principal investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Liu L, Zhang J, Ferguson MK, Appelbaum D, Zhang JX, Pu Y. Developing a clinical and PET/CT volumetric prognostic index for risk assessment and management of NSCLC patients after initial therapy. Front Biosci (Landmark Ed). 2022 01 12; 27(1):16. PMID: 35090321.
      View in: PubMed
    2. Trujillo JA, Godfrey J, Hu Y, Huang J, Smith SM, Frigault MJ, DeFilipp Z, Appelbaum D, Pu Y, Feinberg N, Althaus T, Bishop MR, Riedell PA, Kline J. Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma. Blood. 2021 06 17; 137(24):3454-3459. PMID: 33881502.
      View in: PubMed
    3. He J, Zhang JX, Chen CT, Ma Y, De Guzman R, Meng J, Pu Y. The Relative Importance of Clinical and Socio-demographic Variables in Prognostic Prediction in Non-Small Cell Lung Cancer: A Variable Importance Approach. Med Care. 2020 05; 58(5):461-467. PMID: 31985586.
      View in: PubMed
    4. Sokol EA, Engelmann R, Kang W, Pinto N, Starkey A, Lai H, Nadel H, Shulkin BL, Pu Y, Appelbaum D, Yanik GA, Cohn SL, Armato SG, Volchenboum S. Computer-assisted Curie scoring for metaiodobenzylguanidine (MIBG) scans in patients with neuroblastoma. Pediatr Blood Cancer. 2018 12; 65(12):e27417. PMID: 30198643.
      View in: PubMed
    5. Finkle JH, Penney BC, Pu Y. An updated and validated PET/CT volumetric prognostic index for non-small cell lung cancer. Lung Cancer. 2018 09; 123:136-141. PMID: 30089584.
      View in: PubMed
    6. Pu Y, Zhang JX, Liu H, Appelbaum D, Meng J, Penney BC. Developing and validating a novel metabolic tumor volume risk stratification system for supplementing non-small cell lung cancer staging. Eur J Nucl Med Mol Imaging. 2018 11; 45(12):2079-2092. PMID: 29882161.
      View in: PubMed
    7. Dashevsky BZ, Zhang C, Yan L, Yuan C, Xiong L, Liu Y, Liu H, Kong FS, Pu Y. Whole body metabolic tumor volume is a prognostic marker in patients with newly diagnosed stage 3B non-small cell lung cancer, confirmed with external validation. Eur J Hybrid Imaging. 2017; 1(1):8. PMID: 29782599.
      View in: PubMed
    8. Ginat DT, Westiin C, Brisson RJ, Chin CT, Pu Y, Zhang H, De Souza JA. Pilot Study of 99mTc-labeled Ethylene Dicysteine Deoxyglucose SPECT-CT Imaging in Treatment Response Evaluation in Patients with Locally Advanced Head and Neck Cancer. Cureus. 2017 Apr 11; 9(4):e1152. PMID: 28503388.
      View in: PubMed
    9. Finkle JH, Jo SY, Ferguson MK, Liu HY, Zhang C, Zhu X, Yuan C, Pu Y. Risk-stratifying capacity of PET/CT metabolic tumor volume in stage IIIA non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2017 Aug; 44(8):1275-1284. PMID: 28265739.
      View in: PubMed
    10. Zhu X, Liao C, Penney BC, Li F, Ferguson MK, Simon CA, Wu T, Liu H, Pu Y. Prognostic value of quantitative PET/CT in patients with a nonsmall cell lung cancer and another primary cancer. Nucl Med Commun. 2017 Feb; 38(2):185-192. PMID: 27922540.
      View in: PubMed
    11. Yan L, Zhang H, King M, Wu H, Huang C, Pi W, Pu Y, Tan M, Kong FS. PS01.47: PET Volumetric Prognostic Index may be the Most Significant Survival Factor in Non-Small Cell Lung Cancer Treated with Chemoradiation: Topic: Radiation Oncology. J Thorac Oncol. 2016 Nov; 11(11S):S298-S299. PMID: 27969514.
      View in: PubMed
    12. Xie T, Appelbaum D, Bernard J, Padmanaban M, Pu Y, Gomez C. Evaluation of parkinsonism and striatal dopamine transporter loss in patients with spinocerebellar ataxia type 6. J Neurol. 2016 Nov; 263(11):2302-2307. PMID: 27544504.
      View in: PubMed
    13. Liu H, Chen P, Wroblewski K, Hou P, Zhang CP, Jiang Y, Pu Y. Consistency of metabolic tumor volume of non-small-cell lung cancer primary tumor measured using 18F-FDG PET/CT at two different tracer uptake times. Nucl Med Commun. 2016 Jan; 37(1):50-6. PMID: 26426969.
      View in: PubMed
    14. Obara P, Liu H, Wroblewski K, Zhang CP, Hou P, Jiang Y, Chen P, Pu Y. Quantification of metabolic tumor activity and burden in patients with non-small-cell lung cancer: Is manual adjustment of semiautomatic gradient-based measurements necessary? Nucl Med Commun. 2015 Aug; 36(8):782-9. PMID: 25888358.
      View in: PubMed
    15. Zhang H, Wroblewski K, Jiang Y, Penney BC, Appelbaum D, Simon CA, Salgia R, Pu Y. A new PET/CT volumetric prognostic index for non-small cell lung cancer. Lung Cancer. 2015 Jul; 89(1):43-9. PMID: 25936471.
      View in: PubMed
    16. Zhang C, Liao C, Penney BC, Appelbaum DE, Simon CA, Pu Y. Relationship between Overall Survival of Patients with Non-Small Cell Lung Cancer and Whole-Body Metabolic Tumor Burden Seen on Postsurgical Fluorodeoxyglucose PET Images. Radiology. 2015 Jun; 275(3):862-9. PMID: 25584710.
      View in: PubMed
    17. Obara P, Pu Y. Prognostic value of metabolic tumor burden in lung cancer. Chin J Cancer Res. 2013 Dec; 25(6):615-22. PMID: 24385688.
      View in: PubMed
    18. Pinto N, Cipkala DA, Ladd PE, Pu Y, Cohn SL. Treatment of two cases with refractory, metastatic intermediate-risk neuroblastoma with isotretenoin alone or observation. Pediatr Blood Cancer. 2014 Jun; 61(6):1104-6. PMID: 24293072.
      View in: PubMed
    19. Zhang H, Wroblewski K, Liao S, Kampalath R, Penney BC, Zhang Y, Pu Y. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer. Acad Radiol. 2013 Jan; 20(1):32-40. PMID: 22999369.
      View in: PubMed
    20. Zhang H, Wroblewski K, Pu Y. Prognostic value of tumor burden measurement using the number of tumors in non-surgical patients with non-small cell lung cancer. Acta Radiol. 2012 Jun 01; 53(5):561-8. PMID: 22661603.
      View in: PubMed
    21. Zhang H, Wroblewski K, Appelbaum D, Pu Y. Independent prognostic value of whole-body metabolic tumor burden from FDG-PET in non-small cell lung cancer. Int J Comput Assist Radiol Surg. 2013 Mar; 8(2):181-91. PMID: 22644386.
      View in: PubMed
    22. Liao S, Penney BC, Zhang H, Suzuki K, Pu Y. Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in Stage IV nonsurgical small-cell lung cancer. Acad Radiol. 2012 Jan; 19(1):69-77. PMID: 22142679.
      View in: PubMed
    23. Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, Shih MC, Shimada N, Chen S, Salgia R, Appelbaum DE, Suzuki K, Chen CT, Pu Y. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012 Jan; 39(1):27-38. PMID: 21946983.
      View in: PubMed
    24. Shiraishi J, Appelbaum D, Pu Y, Engelmann R, Li Q, Doi K. Clinical utility of temporal subtraction images in successive whole-body bone scans: evaluation in a prospective clinical study. J Digit Imaging. 2011 Aug; 24(4):680-7. PMID: 20730471.
      View in: PubMed
    25. Huang YE, Chen CF, Huang YJ, Konda SD, Appelbaum DE, Pu Y. Interobserver variability among measurements of the maximum and mean standardized uptake values on (18)F-FDG PET/CT and measurements of tumor size on diagnostic CT in patients with pulmonary tumors. Acta Radiol. 2010 Sep; 51(7):782-8. PMID: 20707663.
      View in: PubMed
    26. Ilkhchoui Y, Appelbaum DE, Pu Y. FDG-PET/CT findings of a metastatic pituitary tumor. Cancer Imaging. 2010 Mar 18; 10:114-6. PMID: 20299302.
      View in: PubMed
    27. Pu Y, Garg A, Corby R, Gao JH, Zeng CM, Pu Y, Li QF. A positive correlation between alpha-glutamate and glutamine on brain 1H-MR spectroscopy and neonatal seizures in moderate and severe hypoxic-ischemic encephalopathy. AJNR Am J Neuroradiol. 2008 Feb; 29(2):216. PMID: 17974609.
      View in: PubMed
    28. Pu Y, Mahankali S, Hou J, Li J, Lancaster JL, Gao JH, Appelbaum DE, Fox PT. High prevalence of pineal cysts in healthy adults demonstrated by high-resolution, noncontrast brain MR imaging. AJNR Am J Neuroradiol. 2007 Oct; 28(9):1706-9. PMID: 17885233.
      View in: PubMed
    29. Shiraishi J, Appelbaum D, Pu Y, Li Q, Pesce L, Doi K. Usefulness of temporal subtraction images for identification of interval changes in successive whole-body bone scans: JAFROC analysis of radiologists' performance. Acad Radiol. 2007 Aug; 14(8):959-66. PMID: 17659242.
      View in: PubMed
    30. Shiraishi J, Li Q, Appelbaum D, Pu Y, Doi K. Development of a computer-aided diagnostic scheme for detection of interval changes in successive whole-body bone scans. Med Phys. 2007 Jan; 34(1):25-36. PMID: 17278486.
      View in: PubMed
    31. Nie Y, Li Q, Li F, Pu Y, Appelbaum D, Doi K. Integrating PET and CT information to improve diagnostic accuracy for lung nodules: A semiautomatic computer-aided method. J Nucl Med. 2006 Jul; 47(7):1075-80. PMID: 16818939.
      View in: PubMed
    Pu's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (118) concept(s)
    _
    Co-Authors Expand Description
    See all (20) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department
    Physical Neighbors Expand Description
    _